InMed Announces Revolutionary Treatment for Dry Age-Related Macular Degeneration
INM-089 IVT formulation selected for continued development Demonstrated successful delivery at doses up to 10 times the projected therapeutic level February 3, 2025 Vancouver, British Columbia–(Newsfile Corp. – February 3, 2025) – InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates…